A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 779 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... December 11, 2021 Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... March 1, 2024 ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December November 26, 2021 New analysis estimates over 21 million UK adults will be obese... May 18, 2022 Load more HOT NEWS Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage... Advances in Gynaecological Cancer Research Could Change the Treatment Landscape ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted...
